[Current options of insulin resistence correction in patients with metabolic syndrome].
OBJECTIVE
To study thiasolidindion drug pioglitazone for efficacy in metabolic syndrome (MS).


METHODS
Twenty patients with MS were examined at baseline and after 12 week therapy with pioglitazone. The examination included estimation of fasting and postprandial glycemia, insulin resistance index, HOMA-IR index, HbAlc, lipid profile, microalbuminuria (MAU), blood pressure, endothelium-related vasodilation.


RESULTS
Pioglitazone therapy for 12 weeks significantly reduced HbAlc, fasting and postprandial glycemia, insulinemia, HOMA-IR, improved blood lipid spectrum, reduced visceral obesity.


CONCLUSIONS
Positive effects were also achieved on blood pressure, MAU and endothelium-related vasodilation.
Demidova
T Iu
TIu
Ametov
A S
AS
Titova
O I
OI
D000419:Albuminuria / Q000453:epidemiology; D004730:Endothelium, Vascular / Q000503:physiopathology; D005215:Fasting; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D050152:Intra-Abdominal Fat / Q000378:metabolism; D008297:Male; D024821:Metabolic Syndrome / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D008875:Middle Aged; D009765:Obesity / Q000453:epidemiology / Q000378:metabolism; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077205:Pioglitazone